​

Gain Therapeutics (GANX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

GANX Stock Forecast

Gain Therapeutics (GANX) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $7.00, with a high of $7.00 and a low of $7.00. This represents a 253.54% increase from the last price of $1.98.

$1 $2 $3 $4 $5 $6 $7 High: $7 Avg: $7 Low: $7 Last Closed Price: $1.98

GANX Stock Rating

Gain Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 7 Strong Sell Sell Hold Buy Strong Buy

GANX Price Target Upside V Benchmarks

TypeNameUpside
StockGain Therapeutics253.54%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$7.00$7.00$7.00
Last Closing Price$1.98$1.98$1.98
Upside/Downside253.54%253.54%253.54%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2533---6
Sep, 2534---7
Aug, 2534---7
Jul, 2534---7
Jun, 2543---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 07, 2025Maxim Group$7.00$1.97255.33%253.54%
Dec 09, 2022Chardan Capital$4.00$3.1526.98%102.02%
Nov 13, 2022Thomas ShraderBTIG$10.00$3.21211.53%405.05%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2025ScotiabankSector PerformOutperforminitialise
Oct 01, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024Maxim GroupBuyBuyhold
Sep 03, 2024H.C. WainwrightBuyBuyhold
Jul 02, 2024H.C. WainwrightBuyBuyhold
Sep 12, 2023MacquarieOutperforminitialise
May 15, 2023Chardan CapitalBuyBuyhold
Dec 09, 2022Chardan CapitalBuyinitialise
Nov 14, 2022EF HuttonBuyBuyhold
Nov 13, 2022BTIGBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.37$-1.48$-1.71$-0.89----
Avg Forecast$-1.57$-1.41$-1.60$-0.96$-0.73$-1.01$-1.08$-1.07
High Forecast$-1.57$-1.41$-1.39$-0.92$-0.53$-0.84$-0.83$-1.07
Low Forecast$-1.57$-1.41$-1.79$-1.04$-1.06$-1.18$-1.33$-1.07
Surprise %-12.74%4.96%6.88%-7.29%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$164.99K$140.11K$55.18K-----
Avg Forecast$149.00K$125.00K$276.00K$33.33K$66.67K$225.00K$225.00K$100.29M
High Forecast$149.00K$125.00K$591.43K$33.33K$66.67K$225.00K$225.00K$100.29M
Low Forecast$149.00K$125.00K$118.28K$33.33K$66.67K$225.00K$225.00K$100.29M
Surprise %10.73%12.09%-80.01%-----

Net Income Forecast

$-25M $-21M $-17M $-13M $-9M $-5M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-13.89M$-17.59M$-22.27M$-20.41M----
Avg Forecast$-20.47M$-18.37M$-22.27M$-12.73M$-10.34M$-13.14M$-14.05M$-13.92M
High Forecast$-20.47M$-18.37M$-18.13M$-11.92M$-6.85M$-10.97M$-10.80M$-13.92M
Low Forecast$-20.47M$-18.37M$-23.24M$-13.55M$-13.83M$-15.31M$-17.30M$-13.92M
Surprise %-32.16%-4.23%-60.33%----

GANX Forecast FAQ

Is Gain Therapeutics stock a buy?

Gain Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Gain Therapeutics is a favorable investment for most analysts.

What is Gain Therapeutics's price target?

Gain Therapeutics's price target, set by 8 Wall Street analysts, averages $7 over the next 12 months. The price target range spans from $7 at the low end to $7 at the high end, suggesting a potential 253.54% change from the previous closing price of $1.98.

How does Gain Therapeutics stock forecast compare to its benchmarks?

Gain Therapeutics's stock forecast shows a 253.54% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Gain Therapeutics over the past three months?

  • October 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Gain Therapeutics’s EPS forecast?

Gain Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.73, marking a -17.98% decrease from the reported $-0.89 in 2024. Estimates for the following years are $-1.01 in 2026, $-1.08 in 2027, and $-1.07 in 2028.

What is Gain Therapeutics’s revenue forecast?

Gain Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $66.67K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $225K, followed by $225K for 2027, and $100.29M for 2028.

What is Gain Therapeutics’s net income forecast?

Gain Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-10.34M, representing a -49.34% decrease from the reported $-20.411M in 2024. Projections indicate $-13.141M in 2026, $-14.052M in 2027, and $-13.922M in 2028.